×
Evotec AG Pre-Tax Profit Margin 2010-2024 | EVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Evotec AG pre-tax profit margin from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
View More
Evotec AG Pre-Tax Profit Margin 2010-2024 | EVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Evotec AG pre-tax profit margin from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.5B
Takeda Pharmaceutical (TAK)
$43.1B
Merck (MKKGY)
$20.8B
Astellas Pharma (ALPMY)
$19.8B
Sandoz Group AG (SDZNY)
$19.4B
United Therapeutics (UTHR)
$17.9B
Summit Therapeutics (SMMT)
$15.3B
Neurocrine Biosciences (NBIX)
$12.9B
Shionogi (SGIOY)
$12.2B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6.1B
Ionis Pharmaceuticals (IONS)
$6B
Crinetics Pharmaceuticals (CRNX)
$4.7B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2.1B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.8B
Xencor (XNCR)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B